<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">De Anda, Carisa</style></author><author><style face="normal" font="default" size="100%">Joseph, Warren</style></author><author><style face="normal" font="default" size="100%">Sandison, Taylor</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tedizolid an Effective Option for Treating ABSSSI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-8</style></pages><abstract><style  face="normal" font="default" size="100%">The antibacterial agent tedizolid is effective against Gram-positive pathogens, including resistant strains of methicillin-resistant Staphylococcus aureus. In the ESTABLISH-1 and -2 trials, it was noninferior to linezolid for treating acute bacterial skin and skin structure infections; this remained true in 3 pooled analyses of these studies, regardless of route of administration, infection type, or whether a causative pathogen was identified at baseline.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>